Research Reports

Review of Dabur's results by Edelweiss Finance

| Updated on January 11, 2018 Published on May 02, 2017

Dabur India (DABUR IN, INR 287, Buy)

Dabur India’s (Dabur) Q4FY17 revenue (down 4.8% YoY) came in line, while EBITDA and PAT (flattish YoY) surpassed estimates led by better-than-expected margin.

Despite strong base of 7% YoY, domestic volumes jumped 2.4% YoY (down 5.0% YoY in Q3FY17). Gross margin dipped by 163bps YoY, but EBITDA margin surged 115bps YoY led by 136bps YoY savings in ad spends and 100bps and 42bps YoY savings in staff and other expenses, respectively.

Dabur gaining market shares in key categories —oral care, hair care, home care, skin, foods — is a positive and we envisage it to be key beneficiary of increasing herbal trend. Maintain ‘BUY’.

Domestic business on recovery road; international operations tepid

Dabur’s domestic business clocked overall growth of 0.1% YoY versus dip of 6.5% YoY in Q3FY17. While toothpaste, foods and health supplements jumped 9.0%, 7.9% and 5.0% YoY, respectively, growth in hair care, home care and OTC & ethicals dipped 4.0%, 6.5% and 4.0% YoY, respectively.

However, market share gains sustained — garnered 30bps in hair oil, 100bps in toothpaste, 70bps in air fresheners, 100bps in mosquito repellent creams and 300bps YoY in juices. International business was impacted by currency devaluation in Egypt, Turkey & Nigeria and economic slowdown in MENA region-reported 4.5% YoY dip in constant currency growth (CCG; flattish in Q3FY17), though growth in local currency was strong.

Q4FY17 conference call: Key takeaways

GST will lead to destocking in Q1FY18 — Dabur and distributors are largely ready for implementation, but lower down the chain preparedness is weak. The company’s rural growth surpassed overall growth in Q4FY17.

Dabur has started regaining some of the lost share in honey; it believes the worst is behind in terms of competition from Patanjali. Shampoo portfolio continued to remain under pressure due to impact on wholesale channel — shifted Vatika to ayurvedic from current herbal positioning.

Outlook and valuations: Positive; maintain ‘BUY’

We expect recovery in volumes and premiumisation on back of new launches and ayurvedic focus. Uptick in rural spending and government’s stimulus remain key triggers. The stock is trading at 29.8x FY19E EPS. We maintain ‘BUY /SO’ with a target price of INR327.

Click here to read full research report

Published on May 02, 2017

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.